Teva UK Limited Launches Generic Ibandronic
CASTLEFORD, England, June 27, 2012
June 27, 2012
We are pleased to announce the launch of generic Ibandronic Acid 150mg film-
Ibandronic Acid is a generic version of Bonviva
(Ibandronic Acid) from Roche.
It is indicated in the treatment of osteoporosis in postmenopausal women at
increased risk of fracture (see section 5.1 of SPC for further details)
Ibandronic Acid is available immediately in the award-winning Teva 360 livery
Strength and pack size
150mg x 1
150mg x 3
Initial Teva retail price
Kim Innes, Commercial Director at Teva, said: "We've now launched 21
products this year including ten on day one of patent expiry, in a variety of
strengths and pack sizes."
New or existing customers can order through their local Teva Territory Sales
Manager, through major wholesalers, or call
To find out more about Teva UK Limited, visit http://www.tevauk.com.
Notes to Editors:
About Teva UK Limited
Teva UK Limited is one of the UK's top ten pharmaceutical manufacturers, with
a presence in the generics, branded respiratory and hospitals markets. It has
the widest range of any UK generic pharmaceutical company and markets solid
and liquid dose, injectable and respiratory medicines to healthcare
professionals. The company is part of Teva Pharmaceutical Industries Ltd.
About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in
, Teva is the world's leading generic drug
maker, with a global product portfolio of more than 1,300 molecules and a
direct presence in about 60 countries. Teva's branded businesses focus on CNS,
oncology, pain, respiratory and women's health therapeutic areas as well as
biologics. Teva currently employs approximately 46,000 people around the
world and reached
in net revenues in 2011.
1. A reduction in the risk of vertebral fractures has been demonstrated;
efficacy on femoral neck fractures has not been established.
For media enquiries, contact the Teva UK Limited Media team on +44(0)1977-
628500, or email firstname.lastname@example.org.